比索洛尔治疗急性心梗后无症状性心肌缺血的疗效及安全性分析

在线阅读 下载PDF 导出详情
摘要   【摘 要】目的:分析比索洛尔治疗急性心梗后无症状性心肌缺血的疗效,并探讨其安全性。方法:将 2017年 5月~ 2019年 12月期间本院接收的 66例急性心梗后无症状性心肌缺血患者作为研究对象,根据单盲分组法将其分成两个组别(对照组和治疗组),对照组以硝苯地平对患者进行治疗,治疗组以比索洛尔对患者进行治疗,观察并对比两组患者临床治疗效果和不良反应发生率。结果:通过对两种患者施以不同药物治疗,可知治疗组患者临床治疗总有效率为 90.9%,明显高于对照组的 69.7%,差异显著,具有统计学意义( P<0.05) ;且治疗组患者不良反应发生率为 12.1%,明显低于对照组的 33.3%,差异显著,具有统计学意义( P<0.05)。结论:在急性心梗后无症状性心肌缺血的治疗中,应用比索洛尔药物治疗方式可以提高临床治疗效果,降低患者不良反应发生率,可广泛推广。    【关键词】比索洛尔 ;急性心梗 ;无症状性 ;心肌缺血    Objective: to analyze the efficacy and safety of bisoprolol in the treatment of asymptomatic myocardial ischemia after acute myocardial infarction. Methods: 66 patients with asymptomatic myocardial ischemia after acute myocardial infarction in our hospital from May 2017 to December 2019 were selected as the research objects, and they were divided into two groups (control group and treatment group) according to single blind grouping method. Patients in control group were treated with nifedipine, while patients in treatment group were treated with bisoprolol The incidence of adverse reactions. Results: the total effective rate of the treatment group was 90.9%, significantly higher than 69.7% of the control group, the difference was statistically significant (P < 0.05); and the incidence of adverse reactions in the treatment group was 12.1%, significantly lower than 33.3% of the control group, the difference was statistically significant (P < 0.05). Conclusion: in the treatment of asymptomatic myocardial ischemia after acute myocardial infarction, bisoprolol can improve the clinical treatment effect and reduce the incidence of adverse reactions, which can be widely promoted.
出处 《世界复合医学》 2020年8期
关键词
出版日期 2020年09月14日(中国期刊网平台首次上网日期,不代表论文的发表时间)